Join us to explore a surprising link: Ketamine and lung cancer outcomes. Intraoperative Ketamine, used during surgery for Non-Small Cell Lung Cancer (NSCLC), is linked to a lower rate of cancer recurrence. This is unexpected for an anesthetic.

But here’s the paradox: a study found that weeks after surgery, the Ketamine group had more circulating rare events (CRE) – tumor-associated cells/fragments in the blood.

How can more of these potentially concerning events mean better long-term results (less recurrence)?

Researchers hypothesize Ketamine might disrupt the tumor environment, increasing shedding. The intriguing idea is that this temporary increase could make shed cancer cells/fragments more visible or vulnerable to the body’s immune system or treatments.

This challenges the simple view that more circulating biomarkers a ...